Total Funding
80
49
Total FundingDebt Financing raised
Growth Score
-2 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
143197
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
- Tom Estok: President & CEO, Director
- Jonathan Powell: Scientific Founder
About the Company
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms
which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.
